Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Anxiety Disorders Overview | 17 | 1 |
| Therapeutics Development | 18 | 2 |
| Pipeline Products for Anxiety Disorders Overview | 18 | 1 |
| Pipeline Products for Anxiety Disorders Comparative Analysis | 19 | 1 |
| Anxiety Disorders Therapeutics under Development by Companies | 20 | 4 |
| Anxiety Disorders Therapeutics under Investigation by Universities/Institutes | 24 | 1 |
| Anxiety Disorders Pipeline Products Glance | 25 | 4 |
| Late Stage Products | 25 | 1 |
| Clinical Stage Products | 26 | 1 |
| Early Stage Products | 27 | 1 |
| Unknown Stage Products | 28 | 1 |
| Anxiety Disorders Products under Development by Companies | 29 | 6 |
| Anxiety Disorders Products under Investigation by Universities/Institutes | 35 | 1 |
| Anxiety Disorders Companies Involved in Therapeutics Development | 36 | 45 |
| AbbVie Inc | 36 | 1 |
| Ache Laboratorios Farmaceuticos S/A | 37 | 1 |
| Adamed Sp. z o.o. | 38 | 1 |
| Addex Therapeutics Ltd | 39 | 1 |
| Amorsa Therapeutics Inc. | 40 | 1 |
| Avineuro Pharmaceuticals, Inc. | 41 | 1 |
| Azevan Pharmaceuticals, Inc. | 42 | 1 |
| Biohaven Pharmaceutical Holding Company Limited | 43 | 1 |
| Bionomics Limited | 44 | 1 |
| Boehringer Ingelheim GmbH | 45 | 1 |
| C4X Discovery Holdings PLC | 46 | 1 |
| Catalyst Pharmaceuticals, Inc. | 47 | 1 |
| Corcept Therapeutics Incorporated | 48 | 1 |
| Edgemont Pharmaceuticals, LLC | 49 | 1 |
| Eisai Co., Ltd. | 50 | 1 |
| Eli Lilly and Company | 51 | 1 |
| Fabre-Kramer Pharmaceuticals, Inc. | 52 | 1 |
| Gabather AB | 53 | 1 |
| GlaxoSmithKline Plc | 54 | 1 |
| GW Pharmaceuticals Plc | 55 | 1 |
| Humanetics Corporation | 56 | 1 |
| IntelGenx Corp. | 57 | 1 |
| Intra-Cellular Therapies, Inc. | 58 | 1 |
| INVENT Pharmaceuticals, Inc. | 59 | 1 |
| Lead Discovery Center GmbH | 60 | 1 |
| Marinus Pharmaceuticals, Inc. | 61 | 1 |
| Merz Pharma GmbH &Co. KgaA | 62 | 1 |
| Neuralstem, Inc. | 63 | 1 |
| Neurelis, Inc. | 64 | 1 |
| NeuroNascent, Inc. | 65 | 1 |
| Newron Pharmaceuticals S.p.A. | 66 | 1 |
| Nippon Chemiphar Co., Ltd. | 67 | 1 |
| Omeros Corporation | 68 | 1 |
| Otsuka Holdings Co., Ltd. | 69 | 1 |
| Pherin Pharmaceuticals, Inc. | 70 | 1 |
| Pragma Therapeutics | 71 | 1 |
| Protagenic Therapeutics Inc. | 72 | 1 |
| Suda Ltd | 73 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 74 | 1 |
| Synchroneuron Inc. | 75 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 76 | 1 |
| Toray Industries, Inc. | 77 | 1 |
| Trevena, Inc. | 78 | 1 |
| TRImaran Pharma, Inc. | 79 | 1 |
| Turing Pharmaceuticals AG | 80 | 1 |
| Anxiety Disorders Therapeutics Assessment | 81 | 14 |
| Assessment by Monotherapy Products | 81 | 1 |
| Assessment by Target | 82 | 5 |
| Assessment by Mechanism of Action | 87 | 4 |
| Assessment by Route of Administration | 91 | 2 |
| Assessment by Molecule Type | 93 | 2 |
| Drug Profiles | 95 | 146 |
| 18-MC Drug Profile | 95 | 1 |
| acamprosate calcium SR Drug Profile | 96 | 2 |
| ACH-36 Drug Profile | 98 | 1 |
| ADN-2013 Drug Profile | 99 | 1 |
| ADX-71441 Drug Profile | 100 | 4 |
| ADX-71743 Drug Profile | 104 | 1 |
| ADX-88178 Drug Profile | 105 | 2 |
| alprazolam Drug Profile | 107 | 1 |
| AM-3506 Drug Profile | 108 | 1 |
| AVN-0189 Drug Profile | 109 | 1 |
| AVN-101 Drug Profile | 110 | 1 |
| AVN-628 Drug Profile | 111 | 1 |
| BNC-210 Drug Profile | 112 | 3 |
| brexpiprazole Drug Profile | 115 | 6 |
| CPP-115 Drug Profile | 121 | 4 |
| D-473 Drug Profile | 125 | 1 |
| Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders Drug Profile | 126 | 1 |
| E-2508 Drug Profile | 127 | 1 |
| evenamide Drug Profile | 128 | 3 |
| FKW-00GA Drug Profile | 131 | 1 |
| fluvoxamine maleate Drug Profile | 132 | 1 |
| ganaxolone Drug Profile | 133 | 5 |
| gepirone hydrochloride ER Drug Profile | 138 | 2 |
| GT-001 Drug Profile | 140 | 1 |
| HL-9001 Drug Profile | 141 | 1 |
| HUF-101 Drug Profile | 142 | 1 |
| IC-87201 Drug Profile | 143 | 1 |
| INT-0036 Drug Profile | 144 | 1 |
| INV-107 Drug Profile | 145 | 1 |
| ITI-007 Drug Profile | 146 | 8 |
| KDAC-0001 Drug Profile | 154 | 1 |
| ketamine hydrochloride Drug Profile | 155 | 1 |
| lorazepam Drug Profile | 156 | 1 |
| lorazepam ER Drug Profile | 157 | 1 |
| LSN-2535717 Drug Profile | 158 | 1 |
| LY-2607540 Drug Profile | 159 | 1 |
| midazolam hydrochloride Drug Profile | 160 | 1 |
| modafinil Drug Profile | 161 | 1 |
| nabiximols Drug Profile | 162 | 7 |
| NC-2800 Drug Profile | 169 | 1 |
| NEO-1940 Drug Profile | 170 | 1 |
| NNI-351 Drug Profile | 171 | 1 |
| NSI-189 Drug Profile | 172 | 4 |
| OMS-527 Drug Profile | 176 | 2 |
| Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders Drug Profile | 178 | 1 |
| PGT-117 Drug Profile | 179 | 1 |
| PH-94B Drug Profile | 180 | 2 |
| PN-6047 Drug Profile | 182 | 1 |
| PT-00114 Drug Profile | 183 | 1 |
| remeglurant Drug Profile | 184 | 1 |
| riluzole Drug Profile | 185 | 3 |
| Rycal Drug Profile | 188 | 1 |
| S-107 Drug Profile | 189 | 1 |
| SCT-66 Drug Profile | 190 | 1 |
| Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile | 191 | 1 |
| Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain Drug Profile | 192 | 1 |
| Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders Drug Profile | 193 | 1 |
| Small Molecule to Antagonize GPR31 for Anxiety Disorders Drug Profile | 194 | 1 |
| Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder Drug Profile | 195 | 1 |
| Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis Drug Profile | 196 | 1 |
| Small Molecule to Target GPR83 for CNS and Immunological Disorders Drug Profile | 197 | 1 |
| Small Molecule to Target Oxytocin for Autism and Anxiety Disorders Drug Profile | 198 | 1 |
| Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders Drug Profile | 199 | 1 |
| Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders Drug Profile | 200 | 1 |
| Small Molecules to Activate Translocator Protein for Anxiety Drug Profile | 201 | 1 |
| Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders Drug Profile | 202 | 1 |
| Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety Drug Profile | 203 | 1 |
| Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Profile | 204 | 1 |
| Small Molecules to Antagonize mGlu2 for Anxiety and Depression Drug Profile | 205 | 1 |
| Small Molecules to Antagonize mGluR3 for Anxiety and Depression Drug Profile | 206 | 1 |
| Small Molecules to Antagonize mGluR5 for Anxiety Drug Profile | 207 | 1 |
| Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders Drug Profile | 208 | 1 |
| Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders Drug Profile | 209 | 1 |
| Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile | 210 | 1 |
| Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy Drug Profile | 211 | 1 |
| Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression Drug Profile | 212 | 1 |
| Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder Drug Profile | 213 | 1 |
| Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder Drug Profile | 214 | 1 |
| Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder Drug Profile | 215 | 1 |
| SRX-246 Drug Profile | 216 | 2 |
| SRX-251 Drug Profile | 218 | 2 |
| STX Drug Profile | 220 | 1 |
| Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder Drug Profile | 221 | 1 |
| TGFK-08AA Drug Profile | 222 | 1 |
| TGSC-01AA(4) Drug Profile | 223 | 1 |
| TNX-102 Drug Profile | 224 | 9 |
| TRV-250 Drug Profile | 233 | 1 |
| UCM-765 Drug Profile | 234 | 1 |
| Vaccine for CNS Disorders Drug Profile | 235 | 1 |
| VAD-1 Drug Profile | 236 | 1 |
| VAD-2 Drug Profile | 237 | 1 |
| VU-0431316 Drug Profile | 238 | 1 |
| VU-0456810 Drug Profile | 239 | 1 |
| ZL-006 Drug Profile | 240 | 1 |
| Anxiety Disorders Dormant Projects | 241 | 15 |
| Anxiety Disorders Discontinued Products | 256 | 5 |
| Anxiety Disorders Product Development Milestones | 261 | 11 |
| Featured News &Press Releases | 261 | 1 |
| Aug 15, 2016: Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Re | 261 | 1 |
| Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder | 262 | 1 |
| Jun 24, 2016: Enrolment Completed in BNC210 Generalised Anxiety Disorder Trial | 262 | 1 |
| Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases | 263 | 1 |
| Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases | 263 | 1 |
| Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases | 264 | 1 |
| Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention | 264 | 1 |
| May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting | 265 | 1 |
| May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting | 266 | 1 |
| May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) | 267 | 1 |
| Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting | 268 | 1 |
| Feb 24, 2016: Biohaven Announces Positive Results from Phase I Study with BHV-0223 | 269 | 1 |
| Jan 13, 2016: Turing Pharmaceuticals Announces Initiation of TUR-002 Clinical Trials | 269 | 1 |
| Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder | 270 | 1 |
| Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 | 270 | 2 |
| Appendix | 272 | 2 |
| Methodology | 272 | 1 |
| Coverage | 272 | 1 |
| Secondary Research | 272 | 1 |
| Primary Research | 272 | 1 |
| Expert Panel Validation | 272 | 1 |
| Contact Us | 272 | 1 |
| Disclaimer | 273 | 1 |